SMWB vs DSGN

Analysts rate Similarweb Ltd.

(SMWB) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Design Therapeutics, Inc.

(DSGN) delivered a total return of -61. 3%, compared to -80. 1% for Similarweb Ltd. (SMWB). Over 10 years, the gap is even starker: DSGN returned -74. 8% versus SMWB's -80. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Design Therapeutics, Inc.

(DSGN) is the lower-risk stock at 1. 59β versus Similarweb Ltd. 's 1. 79β — meaning SMWB is approximately 13% more volatile than DSGN relative to the S&P 500. On balance sheet safety, Design Therapeutics, Inc. (DSGN) carries a lower debt/equity ratio of 0% versus 186% for Similarweb Ltd. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Design Therapeutics, Inc.

grew EPS -38. 6% year-over-year, compared to -178. 6% for Similarweb Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Design Therapeutics, Inc.

(DSGN) is the more profitable company, earning 0. 0% net margin versus -11. 7% for Similarweb Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DSGN leads at 0. 0% versus -8. 3% for SMWB. At the gross margin level — before operating expenses — SMWB leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DSGN: 67.

6% to $17. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Design Therapeutics, Inc.

(DSGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Similarweb Ltd. (SMWB) carries a higher beta of 1. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DSGN: -74. 8%, SMWB: -80. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SMWB (Communication Services) and DSGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.